The CSL share price is up 27% in 12 months

The CSL Limited (ASX:CSL) share price may be up 27% in 12 months, but I don't believe it is too late to invest…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price has been amongst the best performers on the ASX 200 on Friday.

In afternoon trade the biotherapeutics company's shares are up 2% to $198.29.

This latest gain means that the CSL share price is up almost 27% since this time last year.

Why is the CSL share price up 27% in 12 months?

Investors have been fighting to get hold of the company's shares following the release of an impressive full year result in August and an equally strong half year result last month.

In FY 2018 the company reported a net profit after tax of US$1,729 million, which was an increase of 29% on the prior corresponding period.

This was ahead of guidance and driven by strong sales of its Privigen, Hizentra, and IDELVION products and supported by the launch of the HAEGARDA product.

Pleasingly, the company has built on this in FY 2019 with a strong start to the financial year.

Last month CSL report total half year revenue of US$4.5 billion, up 9% on the prior corresponding period. This was the result of the CSL Behring business growing revenue by 8% to US$3,556 million and the Seqirus influenza business delivering a 21% lift in revenue to US$949 million.

On the bottom line the company posted a net profit after tax of US$1.2 billion, up 7% (10% at constant currency) when compared to the prior comparative period. Management also revealed that the company is trending towards the upper end of its full year profit guidance range of US$1,880 million to US$1,950 million. At the top end this represents growth of approximately 13%.

Revenue wasn't the only thing that was growing during the half. CSL spent US$391 million on research and development in the first half of FY 2019, up 14% from US$342.9 million a year earlier.

Whilst expenses are usually something you want to reduce, I'm happy to see CSL's R&D expense increase because of its track record of achieving strong returns on its investments. In addition to this, I believe this high level of R&D will ensure the company stays at the forefront of its key markets long into the future.

Is it too late to invest?

Whilst its shares have rallied hard and are trading on above-average multiples now, I don't believe it is too late to invest.

Nor do analysts at Macquarie who last month rated CSL as a buy with a $230.00 price target. This price target implies potential upside of over 15% for its shares over the next 12 months.

Overall, due to the quality of the company and its strong long-term growth prospects, I think CSL would be a great investment alongside fellow healthcare stars Cochlear Limited (ASX: COH) and ResMed Inc. (ASX: RMD).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Cochlear Ltd. and ResMed Inc. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

A young male ASX investor raises his clenched fists in excitement because of rising ASX share prices today
Share Gainers

3 ASX All Ords shares up 50%+ in March

These ASX shares have been on fire this month. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Share Gainers

Why Mesoblast, Patriot Battery Metals, Sigma, and Zip shares are pushing higher

These shares are having a good session on hump day. But why?

Read more »

Woman looks amazed and shocked as she looks at her laptop.
Consumer Staples & Discretionary Shares

If you'd put $20,000 in this ASX retail stock at the start of 2023, you'd have $134,000 now

This online retailer has executed a remarkable turnaround for its investors.

Read more »

Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
Share Gainers

Here are the top 10 ASX 200 shares today

It was back to earth for ASX shares this Tuesday.

Read more »